XML 31 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2024
Stock-Based Compensation [Abstract]  
Stock-Based Compensation
7. Stock-Based Compensation

 

We have adopted equity incentive plans for which stock options and restricted stock awards are available for grants to employees, consultants and directors. Except for certain options granted to certain Swedish employees, all employee, consultant and director stock options granted under our stock option plans have an exercise price equal to the market value of the underlying common stock on the grant date. There are no vesting provisions tied to performance conditions for any options. Vesting for all outstanding option grants is based solely on continued service as an employee, consultant or director. All of our outstanding stock options and restricted stock awards are classified as equity instruments.

Stock Options and Long-Term Incentive Plan

 

During the year ended December 31, 2020, our stockholders approved the 2020 Plan which replaced our 2015 Stock Incentive Plan (the “2015 Plan”), which in turn replaced our Neonode Inc. 2006 Equity Incentive Plan (the “2006 Plan”). There are no awards outstanding under the 2006 Plan and 2015 Plan. Under the 2020 Plan, 750,000 shares of common stock have been reserved for awards, including nonqualified stock option grants and restricted stock grants to officers, employees, non-employee directors and consultants. The terms of the awards granted under the 2020 Plan are set by our compensation committee at its discretion.

 

In 2020, we established the 2020 LTIP to provide eligible persons with the opportunity to acquire an equity interest, or otherwise increase their equity interest, in the Company as an incentive for them to remain in the service of the Company. Through the 2020 LTIP, eligible employees of Neonode may waive between 50% to 67% of future unearned bonuses that may be awarded to them under the Company’s annual bonus arrangement in exchange for the grant of shares of the Company’s common stock.

  

The following table summarizes the combined activity under all of the stock option plans:

 

   Options Outstanding 
           Weighted-     
           Average     
       Weighted-   Remaining     
       Average   Contractual   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Shares   Price   (in years)   Value 
Options outstanding – January 1, 2023   2,500   $14.40    0.59   $      - 
Options granted   -    -    -    - 
Options exercised   -    -    -    - 
Options cancelled or expired   (2,500)   14.40    -    - 
Options outstanding – December 31, 2023   -   $-    -    - 
Options granted   -    -    -    - 
Options exercised   -    -    -    - 
Options cancelled or expired   -    -    -    - 
Options outstanding and vested – December 31, 2024   -   $-    -   $- 

 

No stock options were granted during the years ended December 31, 2024 and 2023.

 

During the years ended December 31, 2024 and 2023, we recorded no stock-based compensation expense related to the vesting of stock options. The estimated fair value of the stock options will be calculated using the Black-Scholes option pricing model as of the grant date of the stock option.

 

Stock options granted under the 2006, 2015 and 2020 Plans are exercisable over a maximum term of 10 years from the date of grant, vest in various installments over a one to four-year period and have exercise prices reflecting the market value of the shares of common stock on the date of grant.